The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Stock and Other Ownership Interests - BioMarker; MedSIR; Tummi
Honoraria - Boehringer Ingelheim; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Eisai; GlaxoSmithKline; Libbs; MSD Oncology; Novartis; Pfizer; Roche/Genentech; United Medical
Research Funding - AB Science; Abbvie; Abraxis BioScience; Amgen; Asana Biosciences; Astellas Pharma; AstraZeneca; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Clinica Atlantis; Covance; Daiichi Sankyo; Exelixis; GlaxoSmithKline; Halozyme; ImClone Systems; Inc Research; inVentiv Health; Janssen; Leo Pharma; Lilly; Medivation; Merck; Merrimack; Millennium; Mylan; Novartis; Pfizer; Roche/Genentech; Sanofi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; BMS Brazil; MSD Oncology; Novartis; Pfizer; Roche/Genentech
IMpassion130: updated overall survival (OS) from a global, randomized, double-blind, placebo-controlled, Phase III study of atezolizumab (atezo) + nab-paclitaxel (nP) in previously untreated locally advanced or metastatic triple-negative breast cancer (mTNBC).
 
Peter Schmid
Employment - Roche (I)
Honoraria - AstraZeneca; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Merck (Inst); Novartis (Inst); Oncogenex (Inst); Roche (Inst)
 
Sylvia Adams
Consulting or Advisory Role - Bristol-Myers Squibb; Genentech; GlaxoSmithKline; Merck
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Merck (Inst); Novartis (Inst)
 
Hope S. Rugo
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology; Roche/Genentech; Sanofi
 
Andreas Schneeweiss
Honoraria - AstraZeneca; Celgene; Lilly; MSD Oncology; Novartis; Pfizer; Roche Pharma AG; Tesaro
Research Funding - Abbvie; Celgene (Inst); Molecular Partners; Roche Pharma AG (Inst)
Expert Testimony - AstraZeneca; Roche
Travel, Accommodations, Expenses - Celgene; Roche
 
Carlos H. Barrios
No Relationships to Disclose
 
Hiroji Iwata
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Pfizer
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly Japan; Pfizer
Research Funding - AstraZeneca (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Pfizer (Inst)
 
Veronique Dieras
Honoraria - Abbvie; Astellas Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Nektar; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Tesaro
Consulting or Advisory Role - Abbvie; Astellas Pharma; Daiichi Sankyo; Eisai; Lilly; MSD; Nektar; Novartis; Odonate Therapeutics; Pfizer; Roche/Genentech; Seagen; Tesaro
Speakers' Bureau - Eisai; Lilly; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Lilly; Pfizer; Roche
 
Volkmar Henschel
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Luciana Molinero
Employment - Genentech
Stock and Other Ownership Interests - Roche/Genentech
Patents, Royalties, Other Intellectual Property - Genentech
 
Stephen Y. Chui
Employment - Genentech
Stock and Other Ownership Interests - Roche
Patents, Royalties, Other Intellectual Property - Genentech
 
Amreen Husain
Employment - Roche
Stock and Other Ownership Interests - Roche
 
Eric P. Winer
Stock and Other Ownership Interests - Verastem
Honoraria - Carrick Therapeutics; Genentech/Roche; GlaxoSmithKline; Lilly; Tesaro
Consulting or Advisory Role - InfiniteMD; Leap Therapeutics
Research Funding - Genentech (Inst)
 
Sherene Loi
Consulting or Advisory Role - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
Research Funding - Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
 
Leisha A. Emens
Leadership - Society for Immunotherapy of Cancer
Stock and Other Ownership Interests - Molecuvax
Consulting or Advisory Role - Abbvie; Bayer; etheRNA; Gritstone Bio; Macrogenics; Medimmune; Molecuvax; Novartis; Peregrine Pharmaceuticals; Replimune; Syndax
Research Funding - Aduro Biotech; AstraZeneca; Corvus Pharmaceuticals; EMD Serono; Genentech; Maxcyte; Merck; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech; Roche
Other Relationship - Aduro Biotech